Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
NCT ID: NCT02389933
Last Updated: 2021-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
NCT01922089
Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event
NCT02661217
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
NCT02226120
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
NCT03066804
PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
NCT02957409
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LCZ696
immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Is suffering from a serious or life-threatening disease or condition
* Does not have access to a comparable or satisfactory alternative treatment (i.e., comparable or satisfactory treatment is not available or does not exist)
* Patient should be on optimized standard of care treatment, including treatment with ARBs or ACEI, beta-blockers and MRA;
* Intolerance to evidence-based target doses should be documented by the treating physician
* Meets any other relevant medical criteria for compassionate use of the investigational product
Patients eligible for inclusion in this program have to fulfill all of the following criteria:
1. Adult patients (but not younger than 18 year old) will be included, upon completion of written informed consent before any assessment is performed.
2. Patients with a diagnosis of CHF NYHA class II-IV and reduced ejection fraction:
• LVEF ≤ 35% at the time of screening for participation in the program (any local measurement, made within the past 6 months using echocardiography, MUGA, CT scanning, MRI or ventricular angiography is acceptable, provided there are no subsequent measurement above 35%)
3. Patient had a hospitalization for HF within the last 12 months
4. Patients must be on an ACEI or an ARB at a stable dose for at least 4 weeks prior to starting treatment with LCZ696
5. Patients must be treated with a β-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks prior to starting treatment with LCZ696 (reason should be documented for patients not on CHF target doses per local guidelines, or in absence of that medication).
6. An aldosterone antagonist should also be considered in all patients, taking account of renal function, serum potassium and tolerability. If given, the dose of aldosterone antagonist should be optimized according to guideline recommendations and patient tolerability, and should be stable for at least 4 weeks prior to starting treatment with LCZ696
Exclusion Criteria
1. The patient is eligible for participation in any of the IMP's ongoing clinical trials
2. The patient has recently completed a clinical trial that has been terminated and other options (e.g., trial extensions, amendments, etc.) are available to continue a similar treatment.
3. The patient is being transferred from an ongoing clinical trial for which the patient is still eligible for participation
4. History of hypersensitivity or allergy to LCZ696 or to any of its metabolites; to drugs of similar chemical classes, ARBs, or NEP inhibitors; as well as known or suspected contraindications to LCZ696
5. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
6. Previous history of intolerance to recommended target doses of ARBs
7. Known history of angioedema
8. Requirement of concomitant treatment with both ACEIs and ARBs
9. Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy)
10. Symptomatic hypotension and/or a SBP less than 100 mm Hg over the last 4 weeks prior to starting treatment with LCZ696
11. Estimated GFR below 30 mL/min/1.73m2 as measured by the simplified MDRD formula
12. Presence of bilateral renal artery stenosis
13. Serum potassium above 5.2 mmol/L during the week prior to starting treatment with LCZ696
14. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major CV surgery, percutaneous coronary intervention (PCI) or carotid angioplasty within the 3 months prior to starting treatment with LCZ696
15. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months after the schedule date to start treatment with LCZ696
16. Implantation of a cardiac resynchronization therapy pacemaker (CRT-P) or a cardiac resynchronization therapy defibrillator (CRT-D) or upgrading of an existing conventional pacemaker or an implantable cardioverter defibrillator (ICD) to CRT device within 3 months prior to starting treatment with LCZ696, or intent to implant such a device.
Also, patients who had implantation of a conventional pacemaker or an ICD or had a revision of a pacemaker or other device leads within 1 month before starting treatment with LCZ696 are excluded.
17. Heart transplant or ventricular assistance device (VAD) or intent to transplant (on transplant list) or implant a VAD
18. History of severe pulmonary disease
19. Diagnosis of peripartum or chemotherapy induced cardiomyopathy within the 12 months prior to starting treatment with LCZ696
20. Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months prior to starting treatment with LCZ696
21. Symptomatic bradycardia or second or third degree heart block without a pacemaker
22. Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation
23. Presence of other hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic and sub-aortic stenosis
24. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs, including but not limited to any of the following:
* History of active inflammatory bowel disease during the 12 months before starting treatment with LCZ696.
* Current duodenal or gastric ulcers during the 3 months prior to starting treatment with LCZ696
* Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x ULN prior to starting treatment with LCZ696, history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt
* Active treatment with cholestyramine or colestipol resins
25. Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 3 x ULN prior to starting treatment with LCZ696, history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt
26. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (above 5 mIU/mL)
27. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method (if accepted by the local regulatory authority and ethics committee) or a barrier method plus a hormonal method
* Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progesterone agent.
* Reliable contraception should be maintained throughout the treatment and for 7 days after LCZ696 treatment discontinuation
* Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea, or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
28. Presence of any other disease with a life expectancy of \< 3 years
29. Any condition, not identified in the protocol that in the opinion of the treating physician is likely to prevent the patient from safely tolerating LCZ696 or complying with the requirements of the therapy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Vero Beach, Florida, United States
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Novartis Investigative Site
North Ryde, New South Wales, Australia
Novartis Investigative Site
Perth, Western Australia, Australia
Novartis Investigative Site
Krems, , Austria
Novartis Investigative Site
Salzburg, , Austria
Novartis Investigative Site
Sankt Pölten, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Varaždin, HRV, Croatia
Novartis Investigative Site
Limassol, , Cyprus
Novartis Investigative Site
Nicosia, , Cyprus
Novartis Investigative Site
Nicosia, , Cyprus
Novartis Investigative Site
Nicosia, , Cyprus
Novartis Investigative Site
Nicosia, , Cyprus
Novartis Investigative Site
Nicosia, , Cyprus
Novartis Investigative Site
Marseille, Bouches Du Rhone, France
Novartis Investigative Site
Bron, Cedex, France
Novartis Investigative Site
Caen, Cedex, France
Novartis Investigative Site
Saint-Denis, France / La Reunion, France
Novartis Investigative Site
Brest Armees, France, France
Novartis Investigative Site
Amiens, , France
Novartis Investigative Site
Amilly, , France
Novartis Investigative Site
Angers, , France
Novartis Investigative Site
Antibes, , France
Novartis Investigative Site
Aressy, , France
Novartis Investigative Site
Avignon, , France
Novartis Investigative Site
Avignon, , France
Novartis Investigative Site
Bayeux, , France
Novartis Investigative Site
Béziers, , France
Novartis Investigative Site
Bobigny, , France
Novartis Investigative Site
Brest, , France
Novartis Investigative Site
Bron, , France
Novartis Investigative Site
Caen, , France
Novartis Investigative Site
Caen, , France
Novartis Investigative Site
Cambrai, , France
Novartis Investigative Site
Cannes, , France
Novartis Investigative Site
Chambéry, , France
Novartis Investigative Site
Chaumont, , France
Novartis Investigative Site
Cherbourg Octeville, , France
Novartis Investigative Site
Clamart, , France
Novartis Investigative Site
Clermont-Ferrand, , France
Novartis Investigative Site
Compiègne, , France
Novartis Investigative Site
Contamine-sur-Arve, , France
Novartis Investigative Site
Corbeil-Essonnes, , France
Novartis Investigative Site
Cornebarrieu, , France
Novartis Investigative Site
Dijon, , France
Novartis Investigative Site
Eaubonne, , France
Novartis Investigative Site
Honfleur, , France
Novartis Investigative Site
Hyères, , France
Novartis Investigative Site
La Roche-sur-Yon, , France
Novartis Investigative Site
La Seyne-sur-Mer, , France
Novartis Investigative Site
La Tronche, , France
Novartis Investigative Site
Lille, , France
Novartis Investigative Site
Lille, , France
Novartis Investigative Site
Limoges, , France
Novartis Investigative Site
Lyon, , France
Novartis Investigative Site
Lyon, , France
Novartis Investigative Site
Lyon, , France
Novartis Investigative Site
Marseille, , France
Novartis Investigative Site
Marseille, , France
Novartis Investigative Site
Marseille, , France
Novartis Investigative Site
Mâcon, , France
Novartis Investigative Site
Metz, , France
Novartis Investigative Site
Metz-Tessy, , France
Novartis Investigative Site
Monaco, , France
Novartis Investigative Site
Montbéliard, , France
Novartis Investigative Site
Montpellier, , France
Novartis Investigative Site
Montpellier, , France
Novartis Investigative Site
Morlaix, , France
Novartis Investigative Site
Moulins, , France
Novartis Investigative Site
Mulhouse, , France
Novartis Investigative Site
Nantes, , France
Novartis Investigative Site
Neuilly-sur-Seine, , France
Novartis Investigative Site
Nice, , France
Novartis Investigative Site
Nice, , France
Novartis Investigative Site
Nîmes, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Pau, , France
Novartis Investigative Site
Perpignan, , France
Novartis Investigative Site
Pessac, , France
Novartis Investigative Site
Poitiers, , France
Novartis Investigative Site
Pont-l'Abbé, , France
Novartis Investigative Site
Pontarlier, , France
Novartis Investigative Site
Pontoise, , France
Novartis Investigative Site
Rennes, , France
Novartis Investigative Site
Rouen, , France
Novartis Investigative Site
Rumilly, , France
Novartis Investigative Site
Saint-Denis, , France
Novartis Investigative Site
Saint-Denis, , France
Novartis Investigative Site
Saint-Etienne, , France
Novartis Investigative Site
Saint-Etienne, , France
Novartis Investigative Site
Saint-Germain-en-Laye, , France
Novartis Investigative Site
Saint-Palais, , France
Novartis Investigative Site
St.-Jean, , France
Novartis Investigative Site
Strasbourg, , France
Novartis Investigative Site
Thonon-les-Bains, , France
Novartis Investigative Site
Toulouse, , France
Novartis Investigative Site
Toulouse, , France
Novartis Investigative Site
Tours, , France
Novartis Investigative Site
Valence, , France
Novartis Investigative Site
Valenciennes, , France
Novartis Investigative Site
Vandœuvre-lès-Nancy, , France
Novartis Investigative Site
Vichy, , France
Novartis Investigative Site
Villefranche-sur-Saône, , France
Novartis Investigative Site
Wattrelos, , France
Novartis Investigative Site
Süderholz, OT Bartmannshagen, Germany
Novartis Investigative Site
Ahlen, , Germany
Novartis Investigative Site
Augsburg, , Germany
Novartis Investigative Site
Bad Endbach, , Germany
Novartis Investigative Site
Bad Homburg, , Germany
Novartis Investigative Site
Bad Kreuznach, , Germany
Novartis Investigative Site
Bad Krozingen, , Germany
Novartis Investigative Site
Bad Oeynhausen, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Bielefeld, , Germany
Novartis Investigative Site
Bielefeld, , Germany
Novartis Investigative Site
Bonn, , Germany
Novartis Investigative Site
Chemnitz, , Germany
Novartis Investigative Site
Chemnitz, , Germany
Novartis Investigative Site
Chemnitz, , Germany
Novartis Investigative Site
Cologne, , Germany
Novartis Investigative Site
Cologne, , Germany
Novartis Investigative Site
Cologne, , Germany
Novartis Investigative Site
Dessau, , Germany
Novartis Investigative Site
Diepholz, , Germany
Novartis Investigative Site
Dinslaken, , Germany
Novartis Investigative Site
Dortmund, , Germany
Novartis Investigative Site
Dresden, , Germany
Novartis Investigative Site
Dresden, , Germany
Novartis Investigative Site
Dresden, , Germany
Novartis Investigative Site
Düsseldorf, , Germany
Novartis Investigative Site
Eilenburg, , Germany
Novartis Investigative Site
Eschwege, , Germany
Novartis Investigative Site
Essen, , Germany
Novartis Investigative Site
Frankfurt, , Germany
Novartis Investigative Site
Frankfurt, , Germany
Novartis Investigative Site
Frankfurt, , Germany
Novartis Investigative Site
Frankfurt, , Germany
Novartis Investigative Site
Friedrichroda, , Germany
Novartis Investigative Site
Göttingen, , Germany
Novartis Investigative Site
Gronau, , Germany
Novartis Investigative Site
Günzburg, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hanover, , Germany
Novartis Investigative Site
Hanover, , Germany
Novartis Investigative Site
Haßfurt, , Germany
Novartis Investigative Site
Haßloch, , Germany
Novartis Investigative Site
Hohenstein-Ernstthal, , Germany
Novartis Investigative Site
Jena, , Germany
Novartis Investigative Site
Karlsruhe, , Germany
Novartis Investigative Site
Kassel, , Germany
Novartis Investigative Site
Köthen, , Germany
Novartis Investigative Site
Lauchringen, , Germany
Novartis Investigative Site
Leipzig, , Germany
Novartis Investigative Site
Ludwigshafen, , Germany
Novartis Investigative Site
Magdeburg, , Germany
Novartis Investigative Site
Magdeburg, , Germany
Novartis Investigative Site
Mainz, , Germany
Novartis Investigative Site
Mannheim, , Germany
Novartis Investigative Site
Marl, , Germany
Novartis Investigative Site
München, , Germany
Novartis Investigative Site
München, , Germany
Novartis Investigative Site
Münster, , Germany
Novartis Investigative Site
Oldenburg, , Germany
Novartis Investigative Site
Pressath, , Germany
Novartis Investigative Site
Rostock, , Germany
Novartis Investigative Site
Ulm, , Germany
Novartis Investigative Site
Weinheim, , Germany
Novartis Investigative Site
Wildeshausen, , Germany
Novartis Investigative Site
Wolfratshausen, , Germany
Novartis Investigative Site
Würzburg, , Germany
Novartis Investigative Site
Alexandroupoli, Evros, Greece
Novartis Investigative Site
Heraklion - Crete, Greece, Greece
Novartis Investigative Site
Thesaloniki, Greece, Greece
Novartis Investigative Site
Athens, GR, Greece
Novartis Investigative Site
Athens, GR, Greece
Novartis Investigative Site
Athens, GR, Greece
Novartis Investigative Site
Athens, GR, Greece
Novartis Investigative Site
Ioannina, GR, Greece
Novartis Investigative Site
Larissa, GR, Greece
Novartis Investigative Site
Thessaloniki, GR, Greece
Novartis Investigative Site
Thessaloniki, GR, Greece
Novartis Investigative Site
Thessaloniki, GR, Greece
Novartis Investigative Site
Tripoli, GR, Greece
Novartis Investigative Site
Voula, GR, Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Chaïdári, , Greece
Novartis Investigative Site
Chios, , Greece
Novartis Investigative Site
Corfu, , Greece
Novartis Investigative Site
Edessa, , Greece
Novartis Investigative Site
Elefsina, , Greece
Novartis Investigative Site
Glyfada, , Greece
Novartis Investigative Site
Heraklion, , Greece
Novartis Investigative Site
Ioannina, , Greece
Novartis Investigative Site
Kalamata, , Greece
Novartis Investigative Site
Karditsa, , Greece
Novartis Investigative Site
Katerini, , Greece
Novartis Investigative Site
Kavala, , Greece
Novartis Investigative Site
Kilkis, , Greece
Novartis Investigative Site
Kozani, , Greece
Novartis Investigative Site
Marousi, , Greece
Novartis Investigative Site
Piraeus, , Greece
Novartis Investigative Site
Piraeus, , Greece
Novartis Investigative Site
Rio Patra, , Greece
Novartis Investigative Site
Thessaloniki, , Greece
Novartis Investigative Site
Thessaloniki, , Greece
Novartis Investigative Site
Thessaloniki, , Greece
Novartis Investigative Site
Volos, , Greece
Novartis Investigative Site
Co Dublin, Ireland, Ireland
Novartis Investigative Site
Dublin, , Ireland
Novartis Investigative Site
Beirut, , Lebanon
Novartis Investigative Site
Beirut, , Lebanon
Novartis Investigative Site
Beirut, , Lebanon
Novartis Investigative Site
Beirut, , Lebanon
Novartis Investigative Site
Beirut, , Lebanon
Novartis Investigative Site
Beirut, , Lebanon
Novartis Investigative Site
El Achrafiyé, , Lebanon
Novartis Investigative Site
Saida, , Lebanon
Novartis Investigative Site
Tripoli, , Lebanon
Novartis Investigative Site
Msida, , Malta
Novartis Investigative Site
Panama City, , Panama
Novartis Investigative Site
Manila, National Capital Region, Philippines
Novartis Investigative Site
Makati City, , Philippines
Novartis Investigative Site
Manila, , Philippines
Novartis Investigative Site
Ljubljana, , Slovenia
Novartis Investigative Site
Córdoba, Andalusia, Spain
Novartis Investigative Site
Garanada, Andalusia, Spain
Novartis Investigative Site
Jerez de la Frontera, Andalusia, Spain
Novartis Investigative Site
Seville, Andalusia, Spain
Novartis Investigative Site
Utrera, Andalusia, Spain
Novartis Investigative Site
Baleares, Balearic Islands, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site
Bilbao, Basque Country, Spain
Novartis Investigative Site
Galdakano, Basque Country, Spain
Novartis Investigative Site
Villamartín, Cadiz, Spain
Novartis Investigative Site
Santander, Cantabria, Spain
Novartis Investigative Site
Torrelavega, Cantabria, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Lleida, Catalonia, Spain
Novartis Investigative Site
Salt, Catalonia, Spain
Novartis Investigative Site
Badajoz, Extremadura, Spain
Novartis Investigative Site
Pontevedra, Galicia, Spain
Novartis Investigative Site
Logroño, La Rioja, Spain
Novartis Investigative Site
Las Palmas de Gran Canaria, Las Palmas de G.C, Spain
Novartis Investigative Site
Majadahonda, Madrid, Spain
Novartis Investigative Site
San Sebastián de los Reyes, Madrid, Spain
Novartis Investigative Site
San Sebastián de los Reyes, Madrid, Spain
Novartis Investigative Site
Marbella, Malaga, Spain
Novartis Investigative Site
Pamplona, Navarre, Spain
Novartis Investigative Site
Badalona, , Spain
Novartis Investigative Site
El Palmar (Murcia), , Spain
Novartis Investigative Site
Las Palmas de Gran Canaria, , Spain
Novartis Investigative Site
Las Palmas de Gran Canaria, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Salamanca, , Spain
Novartis Investigative Site
Seville, , Spain
Novartis Investigative Site
Seville, , Spain
Novartis Investigative Site
Zaragoza, , Spain
Novartis Investigative Site
Zaragoza, , Spain
Novartis Investigative Site
Lucerne, Canton of Lucerne, Switzerland
Novartis Investigative Site
Abu Dhabi, , United Arab Emirates
Novartis Investigative Site
Ras al-Khaimah, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLCZ696B2318M
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.